GNMSF
Price
$208.35
Change
+$9.00 (+4.51%)
Updated
May 21 closing price
Capitalization
12.83B
RIGL
Price
$19.24
Change
-$1.70 (-8.12%)
Updated
May 23, 02:12 PM (EDT)
Capitalization
352.62M
Interact to see
Advertisement

GNMSF vs RIGL

Header iconGNMSF vs RIGL Comparison
Open Charts GNMSF vs RIGLBanner chart's image
Genmab A/S
Price$208.35
Change+$9.00 (+4.51%)
Volume$224
Capitalization12.83B
Rigel Pharmaceuticals
Price$19.24
Change-$1.70 (-8.12%)
Volume$100
Capitalization352.62M
GNMSF vs RIGL Comparison Chart
Loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNMSF vs. RIGL commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNMSF is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (GNMSF: $208.35 vs. RIGL: $20.94)
Brand notoriety: GNMSF and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNMSF: 7% vs. RIGL: 1%
Market capitalization -- GNMSF: $12.83B vs. RIGL: $352.62M
GNMSF [@Biotechnology] is valued at $12.83B. RIGL’s [@Biotechnology] market capitalization is $352.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNMSF’s FA Score shows that 1 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • GNMSF’s FA Score: 1 green, 4 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, GNMSF is a better buy in the long-term than RIGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNMSF’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 7 bullish TA indicator(s).

  • GNMSF’s TA Score: 4 bullish, 6 bearish.
  • RIGL’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than GNMSF.

Price Growth

GNMSF (@Biotechnology) experienced а +10.35% price change this week, while RIGL (@Biotechnology) price change was +6.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.76%, and the average quarterly price growth was -2.87%.

Reported Earning Dates

RIGL is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($12.8B) has a higher market cap than RIGL($353M). GNMSF has higher P/E ratio than RIGL: GNMSF (12.23) vs RIGL (9.44). RIGL YTD gains are higher at: 24.495 vs. GNMSF (0.468). GNMSF has higher annual earnings (EBITDA): 9.7B vs. RIGL (48.5M). GNMSF has more cash in the bank: 3.23B vs. RIGL (77.1M). RIGL has less debt than GNMSF: RIGL (61.1M) vs GNMSF (143M). GNMSF has higher revenues than RIGL: GNMSF (21.6B) vs RIGL (203M).
GNMSFRIGLGNMSF / RIGL
Capitalization12.8B353M3,626%
EBITDA9.7B48.5M19,992%
Gain YTD0.46824.4952%
P/E Ratio12.239.44130%
Revenue21.6B203M10,640%
Total Cash3.23B77.1M4,184%
Total Debt143M61.1M234%
FUNDAMENTALS RATINGS
GNMSF vs RIGL: Fundamental Ratings
GNMSF
RIGL
OUTLOOK RATING
1..100
172
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
2399
PRICE GROWTH RATING
1..100
5839
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (60) in the null industry is in the same range as RIGL (78) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as GNMSF (100) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's SMR Rating (23) in the null industry is significantly better than the same rating for RIGL (99) in the Biotechnology industry. This means that GNMSF’s stock grew significantly faster than RIGL’s over the last 12 months.

RIGL's Price Growth Rating (39) in the Biotechnology industry is in the same range as GNMSF (58) in the null industry. This means that RIGL’s stock grew similarly to GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (95) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNMSFRIGL
RSI
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
64%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 11 days ago
80%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 11 days ago
81%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
74%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 19 days ago
65%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
73%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 11 days ago
76%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
GNMSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDILX20.22N/A
N/A
BlackRock International Inv A
SUWAX32.90N/A
N/A
DWS Core Equity A
HERTX10.62N/A
N/A
Hartford Emerging Markets Equity R5
CBGAX14.13N/A
N/A
ClearBridge Global Infrastructure Inc C
EEMMF0.37-0.03
-7.50%
E3 LITHIUM LTD.

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
N/A
GMAB - GNMSF
58%
Loosely correlated
+2.49%
RIGL - GNMSF
29%
Poorly correlated
N/A
ARCT - GNMSF
28%
Poorly correlated
N/A
ATNM - GNMSF
27%
Poorly correlated
N/A
AGIO - GNMSF
27%
Poorly correlated
-1.73%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with MNMD. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
N/A
MNMD - RIGL
42%
Loosely correlated
+1.87%
DNLI - RIGL
41%
Loosely correlated
-0.22%
KYMR - RIGL
41%
Loosely correlated
N/A
WVE - RIGL
38%
Loosely correlated
N/A
APGE - RIGL
38%
Loosely correlated
+0.45%
More